Icotrokinra Delivers Complete Skin Clearance Through Week 52 With Strong Safety Profile: Linda Stein Gold, MD

This content was developed independently and is not endorsed by the American Academy of Dermatology.

At the American Academy of Dermatology (AAD) 2026 Annual Meeting, Linda Stein Gold, MD, dermatologist and director of dermatology clinical research at Henry Ford Health System in Detroit, Michigan, discussed new efficacy and safety findings from the ICONIC-ADVANCE 1 (NCT06143878) and ICONIC-ADVANCE 2 (NCT06220604) trials, evaluating the oral peptide icotrokinra (Icotyde; Johnson & Johnson) in patients with moderate to severe plaque psoriasis.

The recent FDA approval of icotrokinra marks an important addition to the treatment landscape. For many dermatologists, hesitancy around oral agents has stemmed from the challenge of balancing efficacy, safety, and tolerability. Icotrokinra appears to address all 3 domains, which may meaningfully shift prescribing patterns toward oral systemic options.

In pivotal clinical trials, icotrokinra was evaluated against placebo and deucravacitinib, a prior benchmark among oral therapies for psoriasis. Icotrokinra demonstrated statistically superior skin clearance, with a more rapid onset of action and approximately double the proportion of patients achieving completely clear skin compared with deucravacitinib. Notably, patients who transitioned from deucravacitinib to icotrokinra showed further improvement over time, with many ultimately reaching clear skin after the switch. These findings suggest that icotrokinra may offer a higher ceiling of efficacy even for those with prior exposure to oral targeted agents.

From a safety and monitoring perspective, icotrokinra may be particularly attractive for both clinicians and payers. Over at least 1 year of follow-up, no new safety signals emerged, and the overall safety profile was comparable with placebo, with lower infection rates than seen with deucravacitinib. The FDA-approved label does not require routine baseline or ongoing laboratory monitoring, except for tuberculosis testing in patients at risk. This absence of mandated lab surveillance could translate into reduced health care utilization, fewer access barriers, and improved adherence—key considerations for managed care decision-makers.

Patient preference is also central to value assessment. Survey data indicate that many patients prefer oral administration over injectable or infusible options. By coupling an oral route of administration with robust efficacy and a streamlined safety monitoring profile, icotrokinra may help meet an important unmet need in psoriasis care while offering potential efficiencies for health care systems and payers.